血浆生物标志物与神经退行性及脑血管病纵向脑萎缩和微血管负荷的关联
该纵向队列研究纳入473例神经退行性或脑血管病患者,随访2年,分析基线血浆GFAP、NfL、p-tau181、p-tau217和Aβ42/40与脑萎缩及小血管病MRI标志物的关联。结果显示这些标志物升高与基线及纵向脑萎缩和WMH负荷加重相关,且在特定疾病亚组中GFAP和NfL与脑萎缩和/或小血管病共病理相关。
要点
- 基线GFAP、NfL、p-tau181、p-tau217升高及Aβ42/40降低与基线脑萎缩和WMH负荷相关。
- 上述标志物亦与纵向脑萎缩和WMH进展相关。
- 在AD/MCI、PD、FTD或CVD亚组中,GFAP和NfL与脑萎缩和/或小血管病共病理相关。
核心结论
- 所选血浆生物标志物似乎可作为真实世界神经退行性和/或脑血管病患者纵向影像变化的预后和监测工具,并有助于理解疾病间共享病理负担的重叠。
研究设计与样本
- 纵向队列研究,纳入安大略神经退行性疾病研究计划中诊断为AD/MCI、PD、FTD或CVD的患者,每年随访共2年。
- 共分析473例患者的1240次MRI,年龄69.2±7.4岁(范围49-87),女性占32.8%。
- 血浆GFAP、NfL、p-tau181、p-tau217和Aβ42/40用Simoa法从基线血样中定量,作为线性混合模型的预测因子。
主要发现
- 在汇总的疾病无关组中,基线GFAP、NfL、p-tau181和p-tau217升高及Aβ42/40降低(程度较小)与基线更严重的脑萎缩和WMH负荷显著相关(|B|=0.02至1.69,p=0.044至<0.001)。
- 在汇总的疾病无关组中,上述标志物与纵向进展显著相关(|B|=0.001至0.028,p=0.049至<0.001)。
- 在疾病特异性队列中,GFAP和NfL与AD/MCI、PD、FTD或CVD的脑萎缩和/或小血管病共病理相关。
- p-tau181和p-tau217与AD/MCI、CVD、PD-MCI或PD-痴呆的脑萎缩和/或小血管病共病理相关。
临床怎么用
- 所选血浆生物标志物似乎可用于真实世界神经退行性和/或脑血管病患者纵向影像变化的预后和监测。
- 这些标志物可能有助于理解不同疾病间共享病理负担的重叠。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Plasma biomarkers of Alzheimer disease (AD), neuroinflammation, and neurodegeneration are increasingly being used in clinical trials for diagnosis and monitoring of dementia. However, their association with longitudinal structural brain MRI changes, an important outcome measure across neurodegenerative and cerebrovascular diseases, is less known. We investigated how baseline plasma biomarkers reflect MRI markers of progression over time in patients with neurodegenerative and cerebrovascular diseases. METHODS: This longitudinal cohort study included patients from the Ontario Neurodegenerative Disease Research Initiative diagnosed with AD or mild cognitive impairment (AD/MCI), Parkinson disease (PD), frontotemporal dementia spectrum disorders (FTD), or cerebrovascular disease (CVD), followed annually for 2 years. Recruitment took place at specialized university-based dementia, movement disorders, and/or stroke clinics in the province of ON, Canada. MRI outcomes included markers of cerebral atrophy (ventricular CSF and regional gray matter volumes) and of small vessel disease pathology (white matter hyperintensity [WMH], perivascular spaces, and lacunar volumes). Hemorrhagic markers at baseline were also included. Plasma levels of glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), phosphorylated tau181 and tau217 (p-tau181, p-tau217), and β-amyloid (Aβ42/40) were quantified from blood samples collected at baseline using Simoa and used as predictors in linear mixed models adjusted for time (months), age, sex, apolipoprotein E (APOE)-ε4 carrier status, kidney function, vascular risk factors, microtubule-associated protein tau (MAPT) diplotypes, waist-hip circumference ratio, and disease duration. RESULTS: We analyzed 1,240 MRIs from 473 patients (age: 69.2 ± 7.4 [range: 49-87]; 32.8% women). Elevated baseline levels of GFAP, NfL, p-tau181, and p-tau217, and to a lesser extent decreased levels of Aβ42/40, were significantly associated with more cerebral atrophy and WMH burden at baseline (|B| = 0.02 to 1.69, p = 0.044 to <0.001) and with progression over time (|B| = 0.001 to 0.028, p = 0.049 to <0.001) in the pooled disease-agnostic group. Within disease-specific cohorts, GFAP and NfL were associated with cerebral atrophy and/or small vessel disease copathology in AD/MCI, PD, FTD, or CVD. P-tau181 and p-tau217 were associated with cerebral atrophy and/or small vessel disease copathology in AD/MCI, CVD, PD-MCI, or PD-dementia. DISCUSSION: Selected plasma biomarkers seem useful as prognosis and monitoring tools of longitudinal imaging changes within real-world populations of neurodegenerative and/or cerebrovascular diseases, and provide insight into overlap across diseases in shared pathologic burden.
引用
- Sanchez E, Coughlan GT, Wilkinson T, et al. Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases. Neurology. 2025. PMID: 40063856. doi:10.1212/WNL.0000000000213438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。